THE EFFICACY AND SAFETY OF MIBEFRADIL IN SUBGROUPS OF PATIENTS WITH CHRONIC STABLE ANGINA-PECTORIS

The pool of controlled clinical studies on mibefradil, a new selective T-type calcium channel blocker, for the treatment of chronic stable a ngina pectoris was analysed to determine the effects in subgroups of p atients defined by age, gender, body weight and common co-existing con ditions. Total exercise tolerance test duration increased similarly in all subgroups, both at 50 mg (range 8.9-17.3%; n=383) and 100 mg mibe fradil (range 23.6-30.8%; n=235), The increases in time to onset of an gina and 1 mm ST-segment depression were similarly comparable. Safety and tolerability was similar to placebo for subgroups at 50 mg, but th e incidence of adverse events was slightly higher in females, older, a nd lower weight patients at the 100 mg dose, particularly in reported leg oedema (7.9% in females vs 1.0% in males and 5.1% in older vs 0% i n younger patients). Mibefradil proved a safe, well tolerated, and eff ective antianginal agent that can be used regardless of demographic fa ctors or of frequent coexisting clinical conditions.